| Citation: |
HE Ru, LIU Xinru, JIANG Wenkai, ZHOU Wence. EMP1 Induces Proliferation and Migration of Pancreatic Cancer Cells by Activating PI3K/AKT Signaling Pathway[J]. Cancer Research on Prevention and Treatment, 2025, 52(3): 193-200. DOI: 10.3971/j.issn.1000-8578.2025.24.0912
|
To investigate the biological behavior of EMP1 in pancreatic cancer cells and the molecular mechanism of EMP1 in promoting tumor progression.
A stable EMP1 knockdown cell line was obtained by lentivirus transfection. The effect of EMP1 on the proliferation of cancer cells was determined by CCK-8 and clonal formation assay. The effect of EMP1 on the migration and invasion of cancer cells was detected by scratch test and Transwell test. The influence of EMP1 on downstream signaling pathways was investigated by Western blot.
The results of qRT-PCR and Western blot showed that EMP1 was highly expressed in pancreatic cancer cells. The results of CCK-8, colony formation, scratch, and Transwell assays indicated that EMP1 promoted the proliferation, migration, and invasion of pancreatic cancer cells. Western blot results revealed that EMP1 might promote tumor progression through the PI3K/AKT signaling pathway.
This study suggested that EMP1 may activate the PI3K/AKT signaling pathway to promote the proliferation, migration, and invasion of pancreatic cancer cells, thereby positively regulating tumor progression.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors[J]. World J Oncol, 2019, 10(1): 10-27. doi: 10.14740/wjon1166
|
| [2] |
Moore A, Donahue T. Pancreatic Cancer[J]. JAMA, 2019, 322(14): 1426. doi: 10.1001/jama.2019.14699
|
| [3] |
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74(1): 12-49.
|
| [4] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34. doi: 10.3322/caac.21551
|
| [5] |
Ilic M, Ilic I. Epidemiology of pancreatic cancer[J]. World J Gastroenterol, 2016, 22(44): 9694-9705. doi: 10.3748/wjg.v22.i44.9694
|
| [6] |
Park W, Chawla A, O'Reilly EM. Pancreatic Cancer: A Review[J]. JAMA, 2021, 326(9): 851-862. doi: 10.1001/jama.2021.13027
|
| [7] |
Liu Y, Ding Y, Nie Y, et al. EMP1 Promotes the Proliferation and Invasion of Ovarian Cancer Cells Through Activating the MAPK Pathway[J]. Onco Targets Ther, 2020, 13: 2047-2055. doi: 10.2147/OTT.S240028
|
| [8] |
Wang J, Li X, Wu H, et al. EMP1 regulates cell proliferation, migration, and stemness in gliomas through PI3K-AKT signaling and CD44[J]. J Cell Biochem, 2019, 120(10): 17142-17150. doi: 10.1002/jcb.28974
|
| [9] |
Wang M, Liu T, Hu X, et al. EMP1 promotes the malignant progression of osteosarcoma through the IRX2/MMP9 axis[J]. Panminerva Med, 2020, 62(3): 150-154.
|
| [10] |
Ahmat Amin MKB, Shimizu A, Zankov DP, et al. Epithelial membrane protein 1 promotes tumor metastasis by enhancing cell migration via copine-Ⅲ and Rac1[J]. Oncogene, 2018, 37(40): 5416-5434. doi: 10.1038/s41388-018-0286-0
|
| [11] |
Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer[J]. Cochrane Database Syst Rev, 2017, 8(8): CD004064.
|
| [12] |
Ni Q, Zhang Y, Tao R, et al. MicroRNA-95-3p serves as a contributor to cisplatin resistance in human gastric cancer cells by targeting EMP1/PI3K/AKT signaling[J]. Aging (Albany NY), 2021, 13(6): 8665-8687.
|
| [13] |
Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside[J]. Semin Cancer Biol, 2019, 59: 125-132. doi: 10.1016/j.semcancer.2019.07.009
|
| [14] |
Yang J, Nie J, Ma X, et al. Targeting PI3K in cancer: mechanisms and advances in clinical trials[J]. Mol Cancer, 2019, 18(1): 26. doi: 10.1186/s12943-019-0954-x
|
| [15] |
Martini M, De Santis MC, Braccini L, et al. PI3K/AKT signaling pathway and cancer: an updated review[J]. Ann Med, 2014, 46(6): 372-383. doi: 10.3109/07853890.2014.912836
|
| [16] |
Xu JC, Chen TY, Liao LT, et al. NETO2 promotes esophageal cancer progression by inducing proliferation and metastasis via PI3K/AKT and ERK pathway[J]. Int J Biol Sci, 2021, 17(1): 259-270. doi: 10.7150/ijbs.53795
|
| [17] |
Song H, Xu Y, Xu T, et al. CircPIP5K1A activates KRT80 and PI3K/AKT pathway to promote gastric cancer development through sponging miR-671-5p[J]. Biomed Pharmacother, 2020, 126: 109941. doi: 10.1016/j.biopha.2020.109941
|
| [18] |
Sobral-Leite M, Salomon I, Opdam M, et al. Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes[J]. Breast Cancer Res, 2019, 21(1): 90. doi: 10.1186/s13058-019-1176-2
|
| [19] |
Jiang W, Kai J, Li D, et al. lncRNA HOXB-AS3 exacerbates proliferation, migration, and invasion of lung cancer via activating the PI3K-AKT pathway[J]. J Cell Physiol, 2020, 235(10): 7194-7203. doi: 10.1002/jcp.29618
|
| [20] |
Liu S, Shi J, Wang L, et al. Loss of EMP1 promotes the metastasis of human bladder cancer cells by promoting migration and conferring resistance to ferroptosis through activation of PPAR gamma signaling[J]. Free Radic Biol Med, 2022, 189: 42-57.
|
| [21] |
Wang Y, Zhang L, Yao C, et al. Epithelial Membrane Protein 1 Promotes Sensitivity to RSL3-Induced Ferroptosis and Intensifies Gefitinib Resistance in Head and Neck Cancer[J]. Oxid Med Cell Longev, 2022, 2022: 4750671.
|
| [22] |
Dong S, Li X, Jiang W, et al. Current understanding of ferroptosis in the progression and treatment of pancreatic cancer[J]. Cancer Cell Int, 2021, 21(1): 480. doi: 10.1186/s12935-021-02166-6
|
| [23] |
Sato A, Rahman NIA, Shimizu A, et al. Cell-to-cell contact-mediated regulation of tumor behavior in the tumor microenvironment[J]. Cancer Sci, 2021, 112(10): 4005-4012. doi: 10.1111/cas.15114
|
| [24] |
Cañellas-Socias A, Cortina C, Hernando-Momblona X, et al. Metastatic recurrence in colorectal cancer arises from residual EMP1+ cells[J]. Nature, 2022, 611(7936): 603-613. doi: 10.1038/s41586-022-05402-9
|
| [25] |
Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism[J]. Nat Rev Cancer, 2020, 20(2): 74-88. doi: 10.1038/s41568-019-0216-7
|
| [26] |
Miao L, Jiang Z, Wang J, et al. Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway[J]. Oncol Rep, 2019, 42(2): 605-614.
|
| [27] |
Wang J, Sun C, Li J, et al. Knockdown of ETV4 promotes autophagy-dependent apoptosis in GBM cells by reducing the transcriptional activation of EMP1[J]. Oncol Lett, 2022, 23(2): 41.
|
| [28] |
Stanciu S, Ionita-Radu F, Stefani C, et al. Targeting PI3K/AKT/mTOR Signaling Pathway in Pancreatic Cancer: From Molecular to Clinical Aspects[J]. Int J Mol Sci, 2022, 23(17): 10132. doi: 10.3390/ijms231710132
|
Figures(6)
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: